A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

British Journal of Cancer
M HarriesS B Kaye

Abstract

A total of 53 women with chemotherapy-naïve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the curve 7 every 3 weeks, followed by four cycles of paclitaxel 70 mg m(-2) (days 1, 8, and 15) and gemcitabine 1000 mg m(-2) (days 1 and 8) every 3 weeks. In all, 37 (70%) had stage III/IV disease, with 22 (42%) having tumour >2 cm; 38 patients (72%) completed all planned treatment; 27 of the 32 (84%) patients with radiologically evaluable disease had partial or complete responses; and 30 of the 39 patients (77%) with elevated cancer antigen (CA) 125 had a greater than 75% fall in this value. At a median follow-up of 28 months, 31 patients had relapsed with a median progression-free survival of 19.5 months. In total, 79% of patients were alive at 2 years. Common Toxicity Criteria grade 3/4 haematological toxicity, predominantly neutropenia, was seen in 57% of the patients. A certain degree of pulmonary toxicity was observed; eight patients had symptomatic breathlessness, +/- decreased diffusing capacity of the lung for carbon monoxide, and interstitial chest X-ray changes during the weekly phase. In all cases, this toxicity was reversible. No significant neurotoxicity was seen. This regimen is general...Continue Reading

References

Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Feb 5, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M FriedlanderL Kayitalire
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A du BoisJ T Thigpen
Sep 2, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G von MinckwitzJ P Neijt
Oct 29, 1999·Journal of Cancer Research and Clinical Oncology·A Sauer-HeilbornK Höffken
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M MuggiaJ M Small
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L ThomasK J O'Byrne
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·G CassinelliF Zunino
Sep 10, 2002·The Lancet Oncology·Mark Harries, Martin Gore
Oct 9, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sumeet BhatiaAlan Sandler
Mar 22, 2003·Gynecologic Oncology·Giuseppe D'AgostinoIgnace Vergote
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·G B KristensenE Vrdoljak

❮ Previous
Next ❯

Citations

May 1, 2007·Women's Health·Fadi Abushahin, Peter G Rose
May 10, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·C J PooleD Roychowdhury
Mar 7, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·L FusoI Vergote
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M FriedlanderP Harnett
Jun 7, 2005·Expert Opinion on Emerging Drugs·Lloyd R Kelland
Jan 13, 2006·British Journal of Cancer·A R ClampUNKNOWN Scottish Gynaecological Cancer Trials Group

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception
X-ray

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.